Neuropathological trademarks of Alzheimer’s disease include synaptic degeneration and neuroinflammation, and studies have investigated biomarkers such as YKL-40 that assess microglial activation and synaptic damage in the course of the disease [153,188,190]. This evidence concerns the gene CHI3L1 and early-onset autosomal dominant Alzheimer disease.